BIO-TECHNE Corp (TECH) Debt Components
- 2026-06-30: Long-term Debt and Lease ObligationUSD $200.00M; Line of Credit Facility, Unused Capacity, Commitment Fee Percentagepure (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Long-term Debt, Current MaturitiesUSD (m).
- 2026-03-31: Long-term Debt and Lease ObligationUSD $200.00M; Line of Credit Facility, Unused Capacity, Commitment Fee Percentagepure (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Long-term Debt, Current MaturitiesUSD (m).
- 2025-12-31: Long-term Debt and Lease ObligationUSD $260.00M; Line of Credit Facility, Unused Capacity, Commitment Fee Percentagepure (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Long-term Debt, Current MaturitiesUSD (m).
- 2025-09-30: Long-term Debt and Lease ObligationUSD $300.00M; Line of Credit Facility, Unused Capacity, Commitment Fee Percentagepure (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Long-term Debt, Current MaturitiesUSD (m).
BIO-TECHNE Corp Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt and Lease Obligation USD | Line of Credit Facility, Unused Capacity, Commitment Fee Percentage pure | Line of Credit Facility, Maximum Borrowing Capacity USD | Long-term Debt, Current Maturities USD | Long-term Line of Credit USD | Notes Payable, Related Parties, Current USD | Notes Payable, Related Parties, Noncurrent USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $200.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $200.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $260.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $300.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $346.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $330.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $300.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $300.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $319.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $389.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $447.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $440.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $350.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $370.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $200.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $264.66M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-08-31 | (m) | 1 month · 0.10% | (m) | (m) | (m) | (m) | (m) |
| 2022-08-31 | (m) | (m) | $1.00B | (m) | (m) | (m) | (m) |
| 2022-06-30 | $243.41M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2022-03-31 | $246.51M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2021-12-31 | $269.62M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2021-09-30 | $287.72M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2021-06-30 | $328.83M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2021-03-31 | $202.93M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2020-12-31 | $219.03M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2020-09-30 | $311.14M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2020-06-30 | $344.24M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2020-03-31 | $407.35M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2019-12-31 | $370.45M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2019-09-30 | $473.56M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2019-06-30 | $492.66M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2019-03-31 | $509.76M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2018-12-31 | $532.87M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $548.97M | (m) | (m) | $12.50M | (m) | (m) | (m) |
| 2018-06-30 | $339.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $392.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $362.50M | (m) | (m) | (m) | $362.50M | (m) | (m) |
| 2017-09-30 | $337.50M | (m) | (m) | (m) | $337.50M | (m) | (m) |
| 2017-06-30 | $343.77M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $343.64M | (m) | (m) | (m) | (m) | $14.58M | (m) |
| 2016-12-31 | $343.66M | (m) | (m) | (m) | (m) | $3.60M | (m) |
| 2016-09-30 | $343.50M | (m) | (m) | (m) | (m) | $3.73M | (m) |
| 2016-06-30 | $91.50M | (m) | (m) | (m) | (m) | $3.76M | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | $91.50M | (m) | (m) |
| 2016-03-31 | $157.81M | (m) | (m) | (m) | $115.50M | $3.81M | (m) |
| 2015-12-31 | $162.79M | (m) | (m) | (m) | $124.00M | $3.79M | (m) |
| 2015-09-30 | $164.37M | (m) | (m) | (m) | $125.50M | $3.87M | (m) |
| 2015-06-30 | $73.00M | (m) | (m) | (m) | (m) | $4.02M | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | $73.00M | (m) | $0.00 |
| 2015-03-31 | $144.00M | (m) | (m) | (m) | (m) | $3.00M | $8.01M |
| 2014-12-31 | $144.00M | (m) | (m) | (m) | (m) | $5.98M | $7.04M |
| 2014-09-30 | $112.00M | (m) | (m) | (m) | (m) | $5.95M | $7.00M |
| 2014-06-30 | $0.00 | (m) | (m) | (m) | (m) | $5.95M | $7.00M |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | $0.00 | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |